Recognition molecules (I) comprising sequences that bind specifically to the glycosylated MUC1 tumor epitope, are new. New recognition molecules (I) comprise: (a) sequences (1) or (2) (b) sequences (3) or (4) and (c) sequences (5) and (6), and bind specifically to the glycosylated MUC1 tumor epitope. Asp-Ala-Trp-Met-Asp (1) Asn-Tyr-Trp-Met-Asn (2) Glu-Ile-Arg-Ser-Lys-Ala-Asn-Asn-His-Ala-Thr-Tyr-Tyr-Ala-Glu-Ser-Val-Lys-Gly (3) Glu-Ile-Arg-Leu-Lys-Ser-Asn-Asn-Tyr-Thr-Thr-His-Tyr-Ala-Glu-Ser-Val-Lys-Gly (4) Gly-Gly-Tyr-Gly-Phe-Asp-Tyr (5) His-Tyr-Tyr-Phe-Asp-Tyr (6) Independent claims are also included for the following: (1) construct (II) comprising (I) fused, chemically coupled or non-covalently associated with additional sequences and/or structures (2) isolated nucleic acid (III) that encodes (I) or (II) (3) expression cassette or vector that contains (III), operatively linked to a promoter (4) virus or host cell comprising at least one cassette or vector of (3) (5) organism containing at least one host cell of (4) (6) method for preparing (I) and (II) and (7) kit containing (I) and/or (II). ACTIVITY : Cytostatic. No details of tests for cytostatic activity are given. MECHANISM OF ACTION : Specific binding to the MUC1 epitope Gene therapy.
